Arrowhead Pharmaceuticals, Inc. (ARWR)
44.49
+0.84
(+1.92%)
USD |
NASDAQ |
Nov 20, 10:01
Arrowhead Pharmaceuticals Free Cash Flow : -283.94M for Sept. 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2026 | -283.94M |
| June 30, 2026 | -75.11M |
| March 31, 2026 | -45.87M |
| December 31, 2025 | 327.01M |
| September 30, 2025 | 156.89M |
| June 30, 2025 | -17.62M |
| March 31, 2025 | 4.596M |
| December 31, 2024 | -576.61M |
| September 30, 2024 | -604.32M |
| June 30, 2024 | -531.98M |
| March 31, 2024 | -470.16M |
| December 31, 2023 | -402.70M |
| September 30, 2023 | -330.63M |
| June 30, 2023 | -342.84M |
| March 31, 2023 | -353.17M |
| December 31, 2022 | -236.21M |
| September 30, 2022 | -188.91M |
| June 30, 2022 | -119.85M |
| March 31, 2022 | -75.00M |
| December 31, 2021 | 123.72M |
| September 30, 2021 | 147.66M |
| June 30, 2021 | 167.24M |
| March 31, 2021 | 165.21M |
| December 31, 2020 | -122.69M |
| September 30, 2020 | -107.34M |
| Date | Value |
|---|---|
| June 30, 2020 | -88.63M |
| March 31, 2020 | -45.76M |
| December 31, 2019 | -34.36M |
| September 30, 2019 | 161.03M |
| June 30, 2019 | 151.66M |
| March 31, 2019 | 129.75M |
| December 31, 2018 | 133.73M |
| September 30, 2018 | -48.64M |
| June 30, 2018 | -54.57M |
| March 31, 2018 | -51.53M |
| December 31, 2017 | -51.39M |
| September 30, 2017 | -31.86M |
| June 30, 2017 | -35.44M |
| March 31, 2017 | -42.87M |
| December 31, 2016 | -42.03M |
| September 30, 2016 | -68.29M |
| June 30, 2016 | -68.25M |
| March 31, 2016 | -62.65M |
| December 31, 2015 | -64.48M |
| September 30, 2015 | -67.68M |
| June 30, 2015 | -66.21M |
| March 31, 2015 | -63.23M |
| December 31, 2014 | -54.75M |
| September 30, 2014 | -37.13M |
| June 30, 2014 | -31.25M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Ionis Pharmaceuticals, Inc. | -622.77M |
| Alnylam Pharmaceuticals, Inc. | 752.13M |
| Nektar Therapeutics | -257.48M |
| Vertex Pharmaceuticals, Inc. | 3.202B |
| TG Therapeutics, Inc. | 85.56M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -192.40M |
| Cash from Investing (Quarterly) | 203.86M |
| Cash from Financing (Quarterly) | -3.702M |
| Free Cash Flow Per Share (Quarterly) | -1.386 |
| Free Cash Flow to Equity (Quarterly) | -220.20M |
| Free Cash Flow to Firm (Quarterly) | -173.39M |
| Free Cash Flow Yield | -4.52% |